New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

DBT + synthesized 2D mammo detects more cancers
Combining digital breast tomosynthesis (DBT) with synthesized 2D mammograph...Read more on AuntMinnie.comRelated Reading: Mammography, DBT safe for accidental exam during pregnancy DBT screening shows value in community practice settings Synthesized mammo plus DBT handles calcifications differently Researchers tout algorithm that predicts breast cancer risk with DBT Is DBT to blame for costlier mammograms? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2021 Category: Radiology Source Type: news

DBT + synthesized 2D mammography detects more cancers
Combining digital breast tomosynthesis (DBT) with synthesized 2D mammograph...Read more on AuntMinnie.comRelated Reading: Mammography, DBT safe for accidental exam during pregnancy DBT screening shows value in community practice settings Synthesized mammo plus DBT handles calcifications differently Researchers tout algorithm that predicts breast cancer risk with DBT Is DBT to blame for costlier mammograms? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2021 Category: Radiology Source Type: news

Patients lack knowledge on radiation in medical imaging
More than half of patients did not know that chest CT delivers more radiatio...Read more on AuntMinnie.comRelated Reading: Consider the esophagus when it comes to breast cancer radiotherapy Radiology contributes to high spending costs in cancer care Mammography, DBT safe for accidental exam during pregnancy Radiation therapy for breast cancer boosts risk of heart disease AI helps reduce cancer PET imaging time and dose (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 13, 2021 Category: Radiology Source Type: news

Chronic stress linked to breast cancer treatment, survival outcomes
Chronic stress may impact treatment completion and survival outcomes for breas...Read more on AuntMinnie.comRelated Reading: Rural women less likely to get colorectal cancer screening Breast MRI can be cost-effective in 4-year screening intervals Mammography, DBT safe for accidental exam during pregnancy Radiation therapy for breast cancer boosts risk of heart disease Immediately reading mammograms helps with workflow, disparities (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 6, 2021 Category: Radiology Source Type: news

Mammography, DBT safe for accidental exam during pregnancy
Digital mammography and digital breast tomosynthesis (DBT) inadvertently performe...Read more on AuntMinnie.comRelated Reading: DBT screening shows value in community practice settings Synthesized mammo plus DBT handles calcifications differently Researchers tout algorithm that predicts breast cancer risk with DBT Immediately reading mammograms helps with workflow, disparities Individualizing risk estimates increase mammography use (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 28, 2021 Category: Radiology Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Better choice of contraceptives can prevent breast cancer
(Ecole Polytechnique F é d é rale de Lausanne) There is a strong link between hormonal contraceptives and breast cancer risk. The main culprit are progestins, synthetic mimics of the pregnancy hormone progesterone that stimulate cell growth in the breast. An EPFL study into the distinct biological effects of different progestins on the breast shows that contraceptive-related breast cancer can be prevented by more informed choices about the composition of contraceptives. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 28, 2021 Category: Biology Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life (HRQoL) and ...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Prenatal detection of heart defects low in Hispanic women, poor areas
Prenatal detection of congenital heart defects with echocardiography can hav...Read more on AuntMinnie.comRelated Reading: Can AI help detect congenital heart disease on fetal ultrasound? Fetal cardiovascular MRI helps diagnose congenital heart defects 3D printing may help to uncover secrets of AAOCA Pregnancy is safe for breast cancer survivors 4D MRI could be big leap forward for fetal heart imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 17, 2021 Category: Radiology Source Type: news

New ultrasound technique detects fetal circulation problems
Researchers have developed a new ultrasound technique to monitor the placent...Read more on AuntMinnie.comRelated Reading: X-ray, CT reveal mummified ancient Egyptian was pregnant Fetal cardiovascular MRI helps diagnose congenital heart defects Lung ultrasound spots COVID-19 in newborns Pregnancy is safe for breast cancer survivors Imaging detects big, rare tumor protruding from fetus's mouth (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 11, 2021 Category: Radiology Source Type: news